CPR Provides Fast, Affordable Repairs for Phones, Tablets, Laptops, and Game Consoles

INDEPENDENCE, OH / ACCESSWIRE / June 24, 2020 / CPR Cell Phone Repair is pleased to announce a new franchise location joining its expanding network of mobile repair stores. The franchise congratulates Fady Kased on the opening of his second CPR store, CPR Cell Phone Repair Belle Vernon in Pennsylvania.

To learn more about CPR Cell Phone Repair Belle Vernon, please visit: https://www.cellphonerepair.com/belle-vernon-pa/

"We are thrilled to now be extending our services in Belle Vernon, with the help of the CPR Belle Vernon team," said Chris Jourdan, Director of Franchise Operations at CPR Cell Phone Repair. "I can guarantee Fady and his staff will deliver quality repair services to the local community residents."

Belle Vernon, Pennsylvania is located in Fayette County, just south of Pittsburgh. It lies along the Monongahela River and adjoins two other counties, Westmoreland to the north and Washington County, on the other side of the river. Belle Vernon, which is French for "beautiful green," was originally laid out by Noah Spears in 1813. The community houses roughly 1,040 residents and is home to several locally-owned restaurants and cafes. CPR Belle Vernon is directly south of Interstate 70 near multiple fast food and shopping areas.

"I'm happy to provide affordable repair solutions to yet another local community," said owner Fady Kased. "My team and I are eager to get started on this new franchise opportunity with the CPR network."

In addition to CPR Belle Vernon, Fady also helps manage CPR Cell Phone Repair Greensburg, which is operated in the Greater Pittsburgh area. His employees are thoroughly trained and committed to delivering exceptional customer service. Each location services broken and malfunctioning electronics such as cell phones, tablets, computers, game consoles, and MP3 players.

CPR Cell Phone Repair Belle Vernon is located at:
850 Rostraver Rd
Belle Vernon, PA 15012

Please contact the store at 724-243-3555 or via email: repairs@cpr-bellevernon.com
Please visit the store's website: https://www.cellphonerepair.com/belle-vernon-pa/

Fady's other store, CPR Greensburg, is located at:
5105 State Route 30 Suite B
Greensburg, PA 15601

About CPR Cell Phone Repair:

Founded in Orlando, Fla. in 1996, CPR Cell Phone Repair is the fastest-growing mobile repair franchise in North America and operates over 850 locations internationally. As a pioneer and leader in the electronics repair industry, CPR offers same-day repair and refurbishing services for cell phones, laptops, gaming systems, digital music players, tablets, and other personal electronic devices. In 2020, CPR was named in Entrepreneur Magazine's Franchise 500 for the fifth consecutive year. Additionally, CPR was ranked in the top 50 of the list and placed second in the Electronics Repairs and Sales franchise business category. For more information about CPR Cell Phone Repair and franchise opportunities, visit https://www.cellphonerepair.com/ or call 877-856-5101.

Contact:

Mark Sweeterman
msweeterman@merrymtg.com
216-674-0645 x617

SOURCE: CPR Cell Phone Repair

ReleaseID: 595075

Adcore Has Now Successfully Entered Greater China, the Second Largest Digital Advertising Market Worldwide with A Projected $128B In Digital Ad Spend During 2020

TORONTO, ON / ACCESSWIRE / June 24, 2020 / Adcore Inc. (the "Company" or "Adcore") (TSXV:ADCO), a leading provider of machine-learning ("ML" and "AI") powered advertising technologies used by digital agencies and advertisers to leverage digital marketing in an effortless and accessible way ("Effortless Advertising"), announced today that it has officially opened its regional headquarters in Hong Kong as part of its strategic expansion in the Greater China region. The Hong Kong facilities and staff are fully operational and will continue to develop in-line with Adcore's growing activity in the region.

The Hong Kong office is led by Mr. Gal Itkin, GM of Adcore Greater China, who has substantial relevant experience in the region and a proven track record of excellence at Adcore prior to his current role.

Adcore's Chief Executive Officer, Omri Brill, commented: "Adcore understands the growing importance of online marketing in Asia, especially the Greater China region, which is projected to reach $128B in digital ad spend this year1. As online marketing in the region is projected to grow rapidly over the next five years as consumer behaviour changes, a need for smart marketing technologies which Adcore provides becomes vital. Adcore has identified Greater China as a strategic market to seize additional business opportunities and to better serve our existing APAC clients."

Mr. Gal Itkin, GM of Adcore Greater China added: "Hong Kong companies are tech-savvy and keen on using smart digital marketing solutions to scale up their business. In addition, the city is close to the Mainland market with many companies setting up regional headquarters here. Having Hong Kong as our regional base will enable us to have better communication with clients and partners in the region as part of our Asia strategy."

1https://www.emarketer.com/content/china-digital-ad-spending-2019

ABOUT ADCORE

Adcore is a leading provider of machine-learning powered advertising technologies used by digital agencies and advertisers to leverage digital marketing in an effortless and accessible way ("Effortless Advertising") with the goal of scaling activity and maximizing ROI.

By combining extensive industry knowledge and experience with its proprietary artificial intelligence engine, Adcore offers a unique digital marketing solution. In addition to being named numerous times on Deloitte's Fast 50 Technology list, Adcore is a certified Google Premier Partner, Microsoft Partner and TikTok Partner.

Established in 2006, the Company employs over forty people in its headquarters in Tel Aviv, Israel and satellite offices in Melbourne, Australia, Toronto, Canada and Hong Kong, Greater China.

For more information about Adcore, please visit https://www.adcore.com/investor

Amounts in this press release are in CAD based on a CAD to USD exchange rate of 1.3516, as of June 23, 2020.

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements, including statements about the Company. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

For further information please contact:

ADCORE INC.

Omri Brill, CEO
Telephone: 647-497-5337
Email: info@adcore.com
Website: www.adcore.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or the accuracy of this release.

SOURCE: Adcore Inc.

ReleaseID: 595058

OAK BROOK, IL / ACCESSWIRE / June 24, 2020 / Affluence Corporation (OTC PINK:AFFU), a diversified technology company focusing on innovative Edge Cloud and 5G enhancing technologies, announced today that the company has executed a Letter of Intent to acquire Flexiscale Technologies Ltd. The terms of the transaction are not available at this time.

"Flexiscale's transformational technology enables users to create Nano Clouds which significantly improve data speed and performance while reducing computing power and costs associated with large data centers," said James E. Honan, Jr. Affluence's CEO. "As 5G is implemented, Flexiscale will enable companies to create their own data centers and clouds. Flexiscale's approach and technology gives us a significant first mover advantage in being able to reduce the size of the data center and deliver edge computing closer to the customer. There is presently nothing like it in the market. According to Gartner, edge computing will be a $700 billion market by 2028," said Honan.

"The Affluence acquisition is very strategic for Flexiscale," said Rajinder Basi, CEO of Flexiscale Technologies Ltd. "We believe that the Flexiscale technology will change the data center paradigm as we know it today. The technology is based on our nano nodes which enables the mass reduction in footprint so the datacenter can exist in a Nano-cloud at the tower base station or be expanded to create micro-clouds or metro-clouds by stringing multiple nodes together using Flexiant, our edge orchestration software. Most large edge computing is still in the development stage, while our technology is in production today. Being part of Affluence will enable Flexiscale to execute on our technology roadmap and solidify industry partnerships," said Basi.

About Affluence Corporation.

Affluence Corporation (AFFU.PK) is a holding company primarily focused on the acquisition and roll-up of synergistic companies providing 5G enhancing infrastructure and technologies, edge computing and innovative cloud solutions. We are investing in mid-market businesses to create a cohesive unit that brings together technology for the next generation of internet.

About Flexiscale

Flexiscale Technologies Ltd is a next generation Edge Cloud Service provider using its scalable modular Edge Cloud Nano Node infrastructure that allows customers and application service providers to rapidly launch their edge applications and services on any Flexiscale Edge Cloud location. Flexiscale Edge Cloud is agile and delivered using its "datacenter in a box" Nano Node, a scalable, innovative and energy efficient "green" technology reducing datacenter footprint. Customers also benefit from a lower operating cost with minimal environmental impact, compute and fast storage, and its Edge Orchestration software, Flexiant.

Partnered with Flexiant, Flexiscale Edge Orchestration provides infrastructure, platform and application services with end to end workflow and business automation, enabling any customers to rapidly deliver cloud solutions through an easy to use self-service cloud interface.

Flexiscale's technology is Telco and Service provider ready, can be located anywhere – on rooftops, underground, factories, offices, 5G locations etc. It enables application providers and data providers, to allow customers to deliver their solutions, applications, and workloads to any Edge location globally. It also provides a range of computer and hybrid cloud services with rapid provisioning of on demand services.

Flexiscale Edge Cloud is a major step change in the evolution of the next generation internet, transforming and transitioning the future of the datacenter and the cloud.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. There are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including: general economic business conditions, competitive and technological factors, markets, services, products and prices, availability and the cost of capital, success of growth initiatives, limited operating history and other factors discussed in our filings with the Securities and Exchange Commissions. Additionally, this release may not be considered as legal, accounting, or investment advice, and is not, and may not be considered, a solicitation for the purchase of any securities issued by Affluence Corporation.

For further information contact Affluence Corporation Investor Relations at 720-295-6409.

SOURCE: Affluence Corporation

ReleaseID: 595065

With More People Staying Home Due to COVID-19, the Indiana-Based Landscaping Company is also Seeing an Increase in Orders for Patio Expansions, Fire Pits and Outdoor Lighting

LOS ANGELES, CA / ACCESSWIRE / June 24, 2020 / The founders of Ben Bush Landscapes, a landscaping company based in Indiana, are currently experiencing a notable increase in the demand for swimming pools.

To learn more about Ben Bush Landscapes and the services that they offer, please check out https://benbushlandscapes.com.

As a company spokesperson noted, due to the current situation with COVID-19, many people are spending more time than ever at home and in their yards. As the weather begins to warm up for summer, homeowners have been inspired to make some changes to their backyards to make them even more attractive and relaxing.

In addition to seeing an increase in demand for swimming pools, the team at Ben Bush Landscapes is also working on a large number of projects that involve patio expansions, fire pits, outdoor fireplaces and outdoor lighting.

"If you are interested in an outdoor living space, have a new swimming pool installation planned or want a vacation in your own backyard please call us. We are certified to install Unilock products to create the most amazing patios, walls, raised hot tubs, fire pits, or water features imaginable," the spokesperson noted, adding that Ben Bush Landscapes serves Evansville and Newburgh, Indiana for Unilock Stone Installation.

As well as swimming pools, fire pits, waterfalls and other beautiful features that are sure to make spending time at home as enjoyable as possible, Ben Bush Landscapes is also ready, willing and able to handle a wide variety of other landscaping projects.

For instance, homeowners who would like to have an attractive retaining wall around their new swimming pool can count on the friendly and experienced team at Ben Bush Landscapes to help; they can also handle planning and installing pavers and flagstone, as well as stone boulders, bulk gravel and beautiful decorative rock.

About Ben Bush Landscapes:

Ben Bush Landscapes Inc. is a new company built on old standards. Officially started in 2003, BBL has quickly gained a reputation for quality and service excellence. The professional staff at BBL has the knowledge and discipline to ensure every project is done right the first time. Their main focus is to create extremely high end unique hard scapes and water feature projects. For more information, please visit https://benbushlandscapes.com.

Contact:

Ben Bush
bbushlandscapes@gmail.com
812-459-4921

SOURCE: Ben Bush Landscapes

ReleaseID: 594359

The coronavirus outbreak has resulted in the emergence of numerous small-scale manufacturers, who are seeking to plug the gap between medical mask supply and demand. Government policy and funding aid will support such growth through the end of the pandemic.

ROCKVILLE, MD / ACCESSWIRE / June 24, 2020 / Healthcare facilities around the world are preparing to keep up with the surge in coronavirus patients. Governments are highly concerned about the capabilities of existing healthcare infrastructure. Shortages of medical supplies are putting patients, doctors, and nurses at risk. The shortages of N-95 masks in particular is gaining attention owing to its importance in healthcare settings.

The global medical mask market is expected to expand at an impressive 9.6% CAGR throughout the period of forecast between 2020 and 2030. As per the Fact.MR study, the unprecedented number of coronavirus cases, coupled with stockpiling behavior by non-healthcare consumers will continue to widen the supply-demand gap in the medical masks market. Bolstering production capacities will be critical to the sustained growth of the industry, during and post the outbreak.

"The rising incidences of contagious respiratory diseases has become the key factor supporting the sales and adoption of medical masks. Rising awareness among the public associated with the efficacy of masks will also help in boosting sales. Growing number of surgeries and need for hospitalization during the crisis period will also help market growth till the end of the pandemic," says the FACT.MR study.

Request a report sample to gain more market insights at-

https://www.factmr.com/connectus/sample?flag=S&rep_id=4732

Medical Mask Market- Key Takeaways

Respirators are projected to account for nearly half of all market revenue, driven by applications in multiple industries including healthcare.
Surgical masks are witnessing substantial growth in terms of sales owing to lower cost and easy access.
Retail pharmacies are the primary channel of distribution owing to high sales of surgical masks.
Hospital pharmacies will contribute majorly to revenue owing to the rise in surgeries and hospital admissions.
High numbers of respiratory disease cases, and easy access to medical mask supplies keeps North America at the forefront of the industry. Asia Pacific is displaying lucrative opportunities owing to government initiatives and awareness campaigns.

Medical Mask Market- Driving Factors

The rapid spread of the coronavirus pandemic has been a major contributor to medical mask sales.
A strong rise in the number of surgery and OPD procedures support demand for medical masks in the healthcare industry.
Growing popularity of online shopping platforms is contributing significantly to sales of medical masks.
Poor hygiene, pollution, and low immunization also contribute to the demand for medical masks.

Medical Mask Market- Major Restraints

The high prevalence of counterfeit products in physical and online distribution channels hurts market prospects.

COVID-19 Impact on Medical Mask Market

Unprecedented demand for products such as N95 respirators and surgical masks in many regions has resulted in existing inventories been sold during the COVID-19 pandemic. Personal protection supplies have reached backorders by months. The shortage has resulted in a major influx of counterfeit products in the market.

Supply and demand will stay apace towards the end of 2020, as manufacturers invest in expanding their production capacities. In addition, governments around the world have provided favorable policies and financial incentives, to optimize supply chains, which will aid in sustained market growth even after the pandemic is brought under control.

Explore the global medical masks market with 185 figures, 34 data tables, along with the table of contents of the report. You can also find detailed segmentation on

https://www.factmr.com/report/4732/medical-mask-market

Competitive Landscape

The medical masks market is fragmented, with a number of small and medium scale businesses leveraging the opportunities arising during the coronavirus crisis. Major players are investing their resources in bolstering production capacities. In addition, research into product innovation has also gained traction. For instance, 3M has increased its global production of medical masks by 200% in early 2020. Also, Boston-based researchers have come up with low cost N95 respirator alternatives.

Prestige Ameritech, 3M, Cardinal Health, Honeywell International Inc., ANSELL Ltd., Halyard Worldwide Inc., Henry Schein Inc., and KCWW, are some of the top medical mask manufacturers in the global market.

About the Report

This study offers readers a comprehensive market forecast of the medical masks market. Global, regional and country-level analysis of the top industry trends impacting the medical masks market is covered in this FACT.MR study. The report offers insights on the medical masks market on the basis of product (surgical mask, N95 respirator, face mask, full-face mask, laryngeal mask, and anesthesia masks), application (respiratory safety, infectious diseases, allergies, and surgeries), and end user (hospitals, diagnostic laboratories, research and academic institutes, individual, and others) across seven regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Explore FACT.MR's Comprehensive Coverage of Healthcare Landscape

High Concentration Respiratory Masks Market– Get the latest insights on the global high concentration respiratory masks market through FACT.MR's report covering analysis for projection period (2018-2028).

Protective Face Mask Market– FACT.MR's study on the global protective face masks market covers trends, tech advancements, players, and strategies for the course of forecast period (2018-2028).

Anti-Pollution Mask Market– Obtain comprehensive analysis on the global anti-pollution mask market through FACT.MR's latest report covering competitive analysis, key regions, along with segmental analysis for 2019-2029.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1485/global-medical-mask-market

SOURCE: Fact.MR

ReleaseID: 595068

WALTHAM, MA / ACCESSWIRE / June 24, 2020 / Tecogen Inc. (OTCQX:TGEN), a clean energy company providing ultra-efficient and clean on-site power, heating and cooling equipment, is pleased to announce the sale of three InVerde e+ microgrid enabled cogenerations systems to a new mixed use building development in Boston, Massachusetts. The units will provide 375 kW of electric power to one of the buildings while simultaneously providing hot water for facility heating and operations. Tecogen's proprietary microgrid controls will allow the system to continue operation during a power outage, a key requirement of the project. Additional buildings within this development are also expected to incorporate the InVerde microgrid solution in the future.

The project required a microgrid study for the Boston Planning and Development Agency (BPDA) which has established microgrid requirements for new construction in Boston to ensure resiliency needs are met as well as to help reduce energy costs, and decrease greenhouse gas (GHG) emissions. The InVerde e+-based microgrid is anticipated to save the facility more than $250,000 a year, reduce the GHG footprint by over 700 tons/year, and provide stand-by power to the building in the case of a grid outage.

"Tecogen worked closely with the engineering company developing the energy plan for this project to ensure that the resiliency and efficiency goals of the owners and city officials were met," noted Stephen Lafaille, Director of Business Development at Tecogen. "We believe the Inverde microgrid solution for this project is a model for future microgrid projects in Massachusetts."

The project will receive incentives via the Mass Save program which provides energy efficiency incentives for combined heat and power systems, and will generate Alternative Energy Credits (AEC's) under the Massachusetts Alternative Portfolio Standard (APS) program, which can be monetized and sold. The project will also qualify for federal tax benefits, including both accelerated depreciation benefits as well as a 10% investment tax credit. The economic incentives, including the AEC and tax benefits, combined to make the investment in Tecogen's InVerde e+ microgrid solution even more attractive to the building owners.

The InVerde e+ cogeneration system incorporates a proprietary microgrid control software which allows the unit to integrate other distributed generation assets such as battery storage, and the ability to function independently from the utility during grid outages. The InVerde e+ also has UL1741 SA "smart inverter" certification which is required for many utilities to provide lucrative grid support services such as demand response, power factor correction, and frequency response. All units will be equipped with Tecogen's proprietary Ultera emissions technology, which reduces criteria emissions to near-zero levels on par with fuel cell technology.

"We are pleased that our InVerde e+ system is a substantial contributor to the energy reduction and resiliency goals for this project" added Benjamin Locke, Tecogen's CEO. "The City of Boston has prioritized the development of microgrids to facilitate local production of energy in ways that can advance cost reduction, sustainability, economic development, and resilience goals. Our InVerde e+ is an ideal solution for achieving these goals."

About Tecogen

Tecogen Inc. designs, manufactures, sells, installs and maintains high efficiency, ultra-clean, cogeneration products including combined heat and power, air conditioning systems and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company provides cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a customer's carbon footprint.

In business for over 35 years, Tecogen has shipped more than 3,000 units, supported by an established network of engineering, sales and service personnel throughout North America. For more information, please visit www.tecogen.com or contact us for a free Site Assessment.

Tecogen, InVerde e+, Ilios, Tecochill, Tecofrost, Tecopower and Ultera are registered or pending trademarks of Tecogen Inc.

Forward Looking Statements

This press release contains "forward-looking statements" which may describe strategies, goals, outlooks or other non-historical matters, or projected revenues, income, returns or other financial measures that may include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," "target," "potential," "will," "should," "could," "likely," or "may" and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date on which they are made and we undertake no obligation to update or revise any forward-looking statements.

In addition to those factors described in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q under "Risk Factors," among the factors that could cause actual results to differ materially from past and projected future results are the following: fluctuations in demand for our products and services, competing technological developments, issues relating to research and development, the availability of incentives, rebates and tax benefits relating to our products and services, changes in the regulatory environment relating to our products and services, integration of acquired business operations, and our ability to obtain financing on favorable terms to fund existing operations and anticipated growth.

Tecogen Media & Investor Relations Contact Information:

Benjamin Locke, CEO
P: (781) 466-6402
E: Benjamin.Locke@Tecogen.com

SOURCE: Tecogen Inc.

ReleaseID: 595072

AGOURA HILLS, CA / ACCESSWIRE / June 24, 2020 / Renowned clinical psychologist and addiction specialist, Dr. Shari Corbitt, will head the Awakenings Treatment Center's new, state-of-the-art detoxification program when it opens September 1st. https://www.awakeningstreatment.com/

The Awakenings Detox program will offer patients safe and supportive recovery from alcohol, opiates and benzodiazapines in a luxurious, private setting. Patients will be housed on the 13,000-square-foot campus of the Awakenings Treatment Center in Old Agoura Hills, and receive 24/7 daily care by licensed medical doctors, nurses, doctoral level psychologists and holistic healthcare practitioners

A licensed psychologist in the state of California, Dr. Corbitt has spent almost two decades providing treatment and therapy to diverse populations across the Southwest. Dr. Corbitt founded the Awakening Treatment Center in 2010, which offers cutting-edge, intensive outpatient healing from chronic pain medication addiction, mental health disorders, eating disorders, trauma, and PTSD.

Dr. Corbitt holds a Doctorate in Clinical Psychology from Yeshiva University in New York. Before founding Awakenings Treatment Center, she worked as Director of Human Services on the Rincon Indian Reservation in Pauma Valley, Calif., as the Clinical Director at Sierra Tucson in Tucson, Ariz., and as Vice President of Promises Treatment Centers in Malibu.

The new Awakenings Detox program will allow Dr. Corbitt and her staff to care for patients in the critical first stages of addiction recovery. Medical detoxification requires controlled administration of medications to soothe the physical symptoms of withdrawal and prevent potentially life-threatening withdrawal effects. The program is licensed by California's Department of Health Care Services, and certified by the American Society of Addiction Medicine, ensuring it meets the highest standards of comfort, safety, and sophistication.

"I'm proud and delighted to lead this new program at Awakenings Treatment Center," Dr. Corbitt said. "We're looking forward to providing our patients with the very best treatment and care right from the start of their recovery journey."

Medical detoxification typically takes three to 10 days on average, depending on the specific drug or drugs a person has abused and the duration of use. Awakenings Detox clients will receive an individualized treatment schedule and timeframe based on their needs. Once the drugs are successfully purged from their bodies, clients will be eligible to move on to the rehabilitation stage of addiction recovery at the Awakenings Treatment Center, where they can receive support for the psychological and emotional aspects of addiction and ensure a sustainable, long-term recovery.

Awakenings Treatment Center is located at 28720 Roadside Drive, Suite 200, in Agoura Hills. For information on admissions, call 855-717-3268 or visit awakeningstreatment.com/admissions.

SOURCE: Awakenings Treatment Center

ReleaseID: 594947

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Reaffirms Expectation to Achieve CDN $20 Million Annualized Revenue and Cash-Flow Breakeven Run Rates This Year

VANCOUVER, BC / ACCESSWIRE / June 24, 2020 / Organto Foods Inc. (TSXV:OGO)(OTC PINK:OGOFF) ("Organto" or the "Company"), an integrated provider of organic and value-added fruits and vegetables today announced the closing of the second and final tranches of its previously announced non-brokered Convertible Note and Equity Financings. Total proceeds of CDN $2,157,500 were included in the second tranches, bringing the total amount to CDN $3,579,195 with CDN $2,075,300 raised via the Convertible Note option and CDN $1,503,895 via the Equity Financing option.

"We are extremely pleased to conclude our financings and as a result are confident this will allow us to leverage the progress we have made in our business and position us for continued exciting growth in the fast-growing healthy eating and organic foods markets. We recently announced that we expect revenues in the second quarter of 2020 to be the largest quarterly revenues in the history of Organto." commented Steve Bromley, Chair and Interim CEO of Organto Foods Inc. "Demand for fresh organic fruits and vegetables continues to grow, driven by increased consumer interest in healthy foods that are produced in a sustainable and transparent manner. We believe our cost-effective and flexible business model has proven its value and that we are well positioned to benefit from this demand. The funds from these financings will be used to expand our supply and range of product offerings and accelerate our growth, enabling our business to ramp up to an annualized revenue run rate of CDN $20 million and achieving cash-flow breakeven by year-end, both key milestones in our strategic plan."

Accendo Banco ("Accendo"), a current strategic investor and lender to Organto, was a key participant in this financing, investing CDN $677,500 in new funds in the Convertible Note financing and reinvesting their current revolving credit facility with Organto in the amount of CDN $677,500 into the Convertible Note. "We truly appreciate the continued support and confidence that Accendo has shown in Organto, and look forward to working closely with them as we execute our plans for the future." Mr. Bromley commented.

A total of CDN $2,075,300 of Convertible Notes were issued in this financing. These notes mature in May and June 2020, carry an annual interest rate of 10% (payable annually), and will be convertible into common shares of Organto at a price of CDN $0.05 per share for one year from the date of issuance and CDN $0.10 per share thereafter until maturity (the "Convertible Notes"). If, at any time after four months from the date of issuance, the closing price of Organto's common shares as traded on the TSX Venture Exchange is equal to or greater than CDN $0.15 for 10 consecutive trading days or more, Organto may, in its sole discretion, accelerate conversion of the Convertible Notes. There is no pre-payment penalty. Organto paid finder's fees of CDN $22,330 in cash and issued 223,300 broker warrants related to the placement of certain of the Convertible Notes. These broker warrants are exercisable at a price of $0.10 and expire in May 2020. Any common shares issued upon the conversion of the Convertible Notes or exercise of the broker warrants will be subject to hold periods expiring in September and October 2020. Included in the Convertible Notes issued were the reinvestment of the revolving credit facility with Accendo Banco in the amount of CDN $677,500, certain short-term loans and accounts payable due to insiders in the amount of CDN $245,750 and CDN $74,550 of promissory notes and interest issued in last year's bridge debt financing (see October 1, 2019 news release).

Funds raised via the Equity Financing option of CDN $1,503,895 were from the sale of 30,077,900 units at CDN $0.05 per unit, with each unit consisting of one common share and one-half common share purchase warrant. Each full warrant entitles the holder thereof to acquire one common share (a "Warrant Share") at a price per Warrant Share of CDN $0.10 with terms of two years expiring in May and June 2022. If, at any time after four months from the date of issue, the closing price of Organto's common shares as traded on the TSX Venture Exchange is equal to or greater than CDN $0.15 for 10 consecutive trading days or more, Organto may, in its sole discretion, accelerate expiry of the warrants. Organto paid finder's fees of CDN $52,073 in cash and issued 520,730 broker warrants related to the Equity Financing. These broker warrants are exercisable at a price of $0.10 and expire in June 2020. The shares issued, as well as any shares issued upon the exercise of the warrants or broker warrants, are subject to hold periods expiring in September and October 2020. Included in the Equity Financing was the settlement of CDN $60,000 of promissory notes issued in last year's bridge financing (see October 1, 2019 news release.

The Convertible Note and Equity Financings remain subject to final acceptance of the TSX Venture Exchange.

2019 and Q-1 2020 Financial Statements

In response to the COVID-19 pandemic, the Canadian Securities Administrators ("CSA") issued a notice on March 18, 2020 stating that securities regulators were providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made on or prior to June 1, 2020. As such the British Columbia Securities Commission ("BCSC") enacted BC Instrument 51-515, Temporary Exemption from Certain Corporate Finance Requirements ("BC 51-515").

On April 28, 2020 Organto announced that due to circumstances created by the COVID-19 pandemic, that it would utilize the temporary exemption under BC 51-515 to file its 2019 annual financial statements. On June 15, 2020 Organto filed its annual financial statements and accompanying management's discussion and analysis, and related CEO and CFO certifications for the financial year ended December 31, 2019.

On May 28, 2020, the Company further announced that it would utilize the temporary exemption as provided by the BCSC with regards to the filing of its unaudited interim quarterly financial statements and accompanying management's discussion and analysis for the quarter ended March 31, 2020 ("Interim Financial Reports"). The Interim Financial Reports would ordinarily have been filed on or before June 1, 2020, the required deadline set by NI 51-102. Organto is relying on the exemption provided in BC Instrument 51-515, Temporary Exemption from Certain Corporate Finance Requirements ("BC 51-515"), which provides the Company with an additional 45 days to file its Interim Financial Reports, which includes the following continuous disclosure documents:

the Company's unaudited financial statements for the quarter ended March 31, 2020 as required by section 4.4 of NI 51-102; and
the Company's Management's discussion and analysis for the quarter ended March 31, 2020 as required by section 5.1(2) of NI 51-102.

The Company expects to file the Interim Financial Reports no later than July 14, 2020.

Until the Company has filed the Financial Reports and Interim Financial Reports management and other insiders of the Company will be subject to a trading black-out, as described in principle in Section 9 of National Policy 11-207. The Company confirms that since the filing of its annual consolidated financial statements for the year ended December 31, 2019, there have been no material business developments other than those already disclosed through news releases.

Stock Option Grants

Organto also announced that it has granted 130,000 stock options to employees as per the terms of the Company's Share Option Plan, all with a strike price of CDN $0.10 with a term of five years, with 20% vesting immediately and 20% on each anniversary thereafter.

Shares for Debt Settlement

Organto also announced that it has entered into an agreement with a service provider to convert CDN $15,000 of amounts due into common shares of the Company at a price of CDN $0.05 per share, subject to approval of the TSX-V.

ON BEHALF OF THE BOARD

Steve Bromley

Chair and Interim Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For more information contact:

Investor Relations
604-634-0970
1-888-818-1364
info@organto.com

ABOUT ORGANTO

Organto's business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people and its shareholders. The Organto Foods Group is an integrated provider of year-round branded, private label and bulk distributed organic and non-GMO vegetables and seasonal organic and non-GMO fruit and vegetable products using an asset-light business model to serve a growing socially responsible and health conscious consumer around the globe.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). In particular, and without limitation, this news release contains forward-looking statements respecting Organto's repositioned business model; Organto's belief that the second quarter of fiscal 2020 will be the largest revenue quarter in the Company's history; Organto's belief that demand for fresh organic fruits and vegetables continues to grow; Organto's belief that its cost-effective and flexible business model is well positioned; Organto's belief that the funds raised will expand supply and product offerings, accelerate growth and position the business for a revenue run-rate of $CDN 20 million and cash-flow breakeven exiting 2020; management's beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto's business model will be implemented; cost increases; dependence on suppliers, partners and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws and similar risks; transportation costs and risks; general business and economic conditions; ongoing relations with distributors, customers, employees, suppliers, consultants, contractors and partners and joint venturers; and risks associated with cannabis operations and receipt of required licenses in Colombia. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.

SOURCE: Organto Foods Inc.

ReleaseID: 595036

VANCOUVER, BC / ACCESSWIRE / June 24, 2020 / Brains Bioceutical announced today that its board of directors has appointed Robin Emerson as Head of Corporate and Social Responsibility, further expanding the company's mandate to place an unprecedented and industry-leading focus on the moral responsibility of a corporation.

Mr. Emerson's mandate includes driving patient advocacy efforts, executing the company's corporate social responsibility strategy, and leading the implementation of best practices for diversity & inclusion. In addition to focusing on social issues of concern to the global community at large, Brains has expanded its commercial footprint by signing a brand deal for a commercial line of all-natural CBD API wellness products focused on Jorja Emerson, the courageous young daughter of Mr. Emerson, and a beacon of hope and inspiration for the Brains team. The acquisition of such a high-profile advocate in the United Kingdom accelerates Brain's mission to become one of the world's largest CBD companies while maintaining our firm grasp on our moral obligations to the communities within which we operate.

"The appointment of my position speaks to Brains' respect for the patients that have fought for legal cannabis access," said Mr. Emerson. "We truly have an opportunity to become one of the most trusted organizations in the space. I also have the opportunity to determine our mandates and to be accountable for Brains' actions here at home and to a larger global audience. Brains is the only CBD company that I have come across with such a strong commitment to social responsibility and patient access, I welcome the opportunity to continue my work as an advocate for patients, parents, children and the less fortunate by partnering with a well-resourced corporate entity such as Brains and the brilliant senior management team of executives at Brains," he continued.

Mr. Emerson has become a fierce leader and advocate in the medical cannabis sector. In 2017, his daughter Jorja-who was just one year old at the time suffered from a rare chromosome deletion and none of the conventional medications worked for her. She suffered vicious seizures; doctors told Mr. Emerson that Jorja would not make it out of intensive care. Mr. Emerson then set off on a journey to find a solution for his daughter.

After speaking with cannabis advocates, political leaders and parents from across the globe, Mr. Emerson was convinced cannabis had the potential to save Jorja. Tireless in his pursuits, Mr. Emerson soon took to the media to fight for change. In 2018, Jorja became one of the first children to get a prescription for medical cannabis in the UK. Jorja's name is now synonymous with pioneering radical reform, courage, and innovative solutions to traditional challenges faced by patients.

Jorja is now four and has been on cannabis medication for 18 months. She is thriving-a far cry from the child that doctors said would not make it. Mr. Emerson continues to advocate for change, working tirelessly with MP's, medical professionals and stakeholders to allow access to natural medications whilst working within complex regulatory frameworks.

Brains Bioceutical is proud to have such a passionate leader join their team as they pursue the companies mandate of providing cost-effective access to safe and reliable cannabinoid-based medicines.

"Brains Bioceutical has already achieved a landmark EUGMP CBD API standard, manufactured here in the UK, and the future plans will change the face of the industry in the UK," said Mr. Emerson. "The icing on the cake is the creation of the Jorja focussed brand and the charitable foundation that will be the legacy of my daughter."

Brains will donate a portion of the profits from Jorja's branded products to the Brains Jorja Emerson Foundation, an organisation that supports low-income families who require access to medical cannabis medication as well as medical tests, family counselling, and special needs equipment.

About Brains Bioceutical Corp:

Brains Bioceutical Corp is a global leader in pharmaceutical, wellness, athletics and veterinary cannabidiol (CBD) based Active Pharmaceutical Ingredient (API) production for commercial use. Our roots lie in nature, the place where exceptional is found. We are one of nine companies in the world to possess the API designation under Eudra GMPD and one of three in the world certified to produce from a natural, plant-based source. Our CBD API product lines are THC-free, non-GMO and produced in wholly-owned BSPG Laboratories in the UK. Forever advancing and enriching, Brains is involved in international clinical trials, including a phase 3, double-blind clinical trial using CPB API for treatment of refractory epilepsy, exclusively supplied by Brains Bioceutical. ALTIS / Brains Bioceutical Living Lab, a state-of-the-art, interdisciplinary athletics training facility, explores, experiments, and evaluates the power of CBD API in elite athletes. With a rare hybrid of pharmaceutical and consumer goods executives, the Brains Bioceutical senior management team works with the science of nature, never against it, extracting its power to help make better.

CAUTIONARY STATEMENT: This news release contains forward-looking statements or forward-looking information ("forward-looking statements") within the meaning of securities laws. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

CONTACT:

Calvin Rasode,
Director of Marketing
1-855-927-2476
calvin@brainsbio.com
www.brainsbio.com

SOURCE: Brains Bioceutical Corp.

ReleaseID: 594974

Robot Cache is the First Digital Storefront That Allows Customers to Retain Value by Reselling Games and Provides Incremental Resale Revenue to Developers and Publishers

NEW YORK, NY / ACCESSWIRE / June 24, 2020 / Atari® (OTC PINK:PONGF) – one of the world's most iconic consumer brands and entertainment producers – today announced a partnership with revolutionary PC video game distribution platform Robot Cache to integrate the Atari Token into the Robot Cache digital storefront where customers can buy or resell digital games. Through this partnership, customers reselling and buying digital PC titles through Robot Cache will be able to utilize Atari's blockchain-based cryptocurrency – Atari Token – for all of their transactions.

"We are pleased to announce the integration of the Atari Token into Robot Cache's unique offerings that benefit both customers and the creators of some of today's best video games," said Fred Chesnais, Atari CEO. "Our goal is to make the Atari Token a ubiquitous digital currency. With the addition of Robot Cache to our list of top-notch partners, we are a significant step closer to realizing that vision."

"The Atari brand is beloved by gamers and consumers, and we're excited to work with them to offer the Atari Token as a payment option on Robot Cache," said Lee Jacobson, Robot Cache CEO. "Conceived and backed by the company that essentially launched the video game industry, the Atari Token is a uniquely entertainment-focused currency, and we think it's a perfect means of adding cryptocurrency-based commerce of digital games on our platform."

Founded by video game industry veterans Brian Fargo, Lee Jacobson, and Mark Caldwell, Robot Cache is the first PC storefront that allows gamers to resell video games from their digital content libraries. Robot Cache features a curated selection of popular games from top developers and publishers, with a visual-centric platform user interface that aids in the discoverability of new titles and emphasizes their unique attributes.

Developers and publishers of titles available through Robot Cache enjoy higher margins thanks to a 5% distribution fee (versus the industry average of 30%) and keep 95% of all new game sales and 70% of resold copies through the storefront with users receiving 25%. Utilizing the Robot Cache client, customers can additionally mine IRON – a platform-specific digital currency – to buy content on the storefront.

To learn more about Robot Cache, please visit https://store.robotcache.com.

Atari Chain Ltd. is a subsidiary of Atari SA, created to lead the development of ongoing projects in the field of cryptocurrencies in entertainment-based industries. The Atari Token, currently slated to launch by September of 2020, is issued by Atari Chain, Ltd (Gibraltar), a company equally owned by Atari and the ICICB Group.

For more information on the Atari Token, please join Atari Telegram at https://t.me/AtariTokenOfficial and visit atarichain.com.

To stay up-to-date on all things Atari and retro-pop-culture, follow on Facebook, Twitter, and Instagram.

About Atari

Atari® is an interactive entertainment company. As an iconic brand that transcends generations and audiences, the company is globally recognized for its multi-platform, interactive entertainment, and licensed products. Atari owns and/or manages a portfolio of more than 200 games and franchises, including world-renowned brands like Asteroids®, Centipede®, Missile Command®, Pong®, and RollerCoaster Tycoon®. Atari has offices in New York and Paris.

Visit us online at www.atari.com.

About Robot Cache

Robot Cache is the first-ever decentralized PC video game distribution platform with a revolutionary digital resale model utilizing the blockchain. Robot Cache allows publishers to keep significantly more revenues than other distribution platforms and gives gamers, for the first time ever, the ability to re-sell their digital games.

Robot Cache's advisory board includes a mix of video game and blockchain experts: Anna Sweet, Nolan Bushnell, Michael Maloney, Chris Keenan, Jayson Dubin, Scott Walker, and Keven Baxter. For more information, please visit www.robotcache.com or follow @RobotCache at Twitter or RobotCache on Facebook.

###

PRESS CONTACT

For Atari:
Mario R. Kroll and CJ Melendez
UberStrategist Inc.
pr@uberstrategist.com
1-646-844-8388

For Robot Cache:
Jim Redner
jimredner@therednergroup.co

SOURCE: Atari

ReleaseID: 594952